期刊
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
卷 12, 期 2, 页码 126-137出版社
WILEY
DOI: 10.1111/jth.12472
关键词
cardiovascular diseases; inflammation; isoprostanes; platelets; thromboxane receptors
资金
- Evolva [EV-077]
- Sanofi-Aventis
- Eli Lilly
- Daiichi Sankyo
- Medicines Company
- AstraZeneca
- Evolva
- Bristol Myers Squibb
- Merck
- Abbott Vascular
- PLx Pharma
- Glaxo Smith Kline
- Otsuka
- Esther and King Biomedical Research Grant
- Bristol Meyers Squibb
- Lilaas
- Ablynx
- Cardiolynx
- Bird and Bird
The activation of thromboxane prostanoid (TP) receptor on platelets, monocytes/macrophages, endothelial cells, and vascular smooth muscle cells (SMC) plays important roles in regulating platelet activation andvascular tone and in the pathogenesis of thrombosis and vascular inflammation. Oxidative stress and vascular inflammation increase the formation of TP receptor agonists, which promote initiation and progression of atherogenesis and thrombosis. Furthermore, TP receptor activation promotes angiogenesis and vessel wall constriction. Besides thromboxane A(2) and its endoperoxide precursors, prostaglandin G(2) and H-2, isoprostanes, and 20-hydroxyeicosatetraenoic acid also activate TP receptor as autocrine or paracrine ligands. These additional TP activators play a role in pathological conditions such as diabetes, obesity, and hypertension, and their biosynthesis is not inhibited by aspirin, at variance with that of thromboxane A(2). The understanding of TP receptor function increased our current knowledge of the pathogenesis of atherosclerosis and thrombosis, highlighting the great impact that this receptor has in cardiovascular disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据